QIAGEN Clinical Insight bioinformatics platform

Wednesday, 27 May, 2015 | Supplied by: QIAGEN Pty Ltd


QIAGEN has announced the launch of the QIAGEN Clinical Insight (QCI) bioinformatics content and software platform for clinical testing labs to interpret and report on genomic variants identified in next-generation sequencing (NGS). The first two supported applications for the bioinformatics platform are in oncology, for somatic and hereditary cancer testing.

The platform is an evidence-based decision support solution that evaluates genomic variants in the context of published biomedical literature, professional association guidelines, publicly available databases and annotations, drug labels and clinical trials. Using a powerful software platform, the secure QCI web application and QIAGEN’s private data centre, clinicians can rapidly classify variants, identify treatment options and perform geographical clinical trial matching.

The product supports both germline and somatic test indication, which is important to labs offering diverse test indications. It provides full platform- and assay-agnostic interpretation and reporting workflow support, which enables clinical testing labs to reduce time and cost associated with NGS-based testing. It also provides access to the Allele Frequency Community, a large repository of ancestral and ethnic diversity data.

Online: www.qiagen.com
Phone: 03 9840 9800
Related Products

Enzo Life Sciences SUPERKILLERTRAIL protein (soluble) (human), (recombinant)

Enzo Life Sciences' SUPERKILLERTRAIL (soluble) (human), (recombinant) is an enhanced ligand...

Diaclone ELISpot Kits

Diaclone's ELISpot Kits are highly specific immunoassays for the analysis of the production...

Bio-Rad Laboratories Bio-Plex Pro Human SARS-CoV-2 Variant Neutralization Antibody Assays

The assays allow scientists to measure neutralising antibodies quickly and efficiently against...


  • All content Copyright © 2022 Westwick-Farrow Pty Ltd